Which agents should we use to treat and prevent influenza in 2006-2007?

Sherif B. Mossad, MD
Department of Infectious Diseases, Cleveland Clinic; associate professor of medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University

Address: Sherif B. Mossad, MD, Department of Infectious Diseases, S32, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail mossads@ccf.org

The author has indicated that he has received a grant from Roche corporation and is the primary investigator at Cleveland Clinic for a multicenter study of oseltamivir to prevent influenza in transplant patients.

Sherif B. Mossad, MD
Department of Infectious Diseases, Cleveland Clinic; associate professor of medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University

Address: Sherif B. Mossad, MD, Department of Infectious Diseases, S32, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail mossads@ccf.org

The author has indicated that he has received a grant from Roche corporation and is the primary investigator at Cleveland Clinic for a multicenter study of oseltamivir to prevent influenza in transplant patients.

Sherif B. Mossad, MD
Department of Infectious Diseases, Cleveland Clinic; associate professor of medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University

Address: Sherif B. Mossad, MD, Department of Infectious Diseases, S32, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail mossads@ccf.org

The author has indicated that he has received a grant from Roche corporation and is the primary investigator at Cleveland Clinic for a multicenter study of oseltamivir to prevent influenza in transplant patients.